(Q33725822)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

0 references

0 references

Donald R. VanDevanter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

David J Pasta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Jeffrey S Wagener

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Lawrence Rasouliyan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Warren E Regelmann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Wayne J Morgan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Michael W Konstan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

8 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

published in

Pediatric Pulmonology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

666-673

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

11 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Pulmonary exacerbations in cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

The changing microbial epidemiology in cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Ten years of viral and non-bacterial serology in adults with cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Update on treatment of pulmonary exacerbations in cystic fibrosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Cystic fibrosis pulmonary exacerbations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Defining a pulmonary exacerbation in cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Predictive 5-year survivorship model of cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Spirometric reference values from a sample of the general U.S. population

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049300

Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis.

21 June 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Pulmonary function growth velocity in children 6 to 18 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Factors influencing outcomes in cystic fibrosis: a center-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22652

Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis

21 January 2018

1 reference

12 December 2020

Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis

1 reference

12 December 2020

The role of respiratory viruses in cystic fibrosis

1 reference

12 December 2020

Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis

1 reference

12 December 2020

Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis

1 reference

12 December 2020

Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers

1 reference

12 December 2020

Defining an exacerbation of pulmonary disease in cystic fibrosis

1 reference

12 December 2020

Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!

1 reference

12 December 2020

Pulmonary exacerbations in cystic fibrosis

1 reference

12 December 2020

Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis

1 reference

12 December 2020

Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada

1 reference

12 December 2020

Identifiers

DOI

10.1002/PPUL.22652

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

release_iubph4y67vgf7n275o3p7dzgcy

11 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iubph4y67vgf7n275o3p7dzgcy

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

PubMed publication ID

22888106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22888106%20AND%20SRC:MED&resulttype=core&format=json